Cephalon Announces Enrollment In the Risk Evaluation and Mitigation Strategy Program for FENTORA and ACTIQ

Thursday October 13th 2011 02:55:00 PM

FRAZER, Pa., October 13, 2011 – Cephalon, Inc. (Nasdaq: CEPH) announced that healthcare professionals, pharmacies, and distributors who prescribe and dispense FENTORA® (fentanyl buccal tablet) [C-II] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II] can enroll in the recently approved Risk Evaluation and Mitigation Strategy (REMS) program.  The primary method for prescriber and pharmacy enrollment is online at www.actiqandfentorarems.com.  A call center is available to provide additional support and information at 1-888-688-6885. Under this REMS, healthcare professionals and pharmacies who prescribe and dispense FENTORA and ACTIQ enroll by completing an education module and ...

Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015

Monday August 22nd 2011 08:36:00 AM

FRAZER, Pa., Aug. 22, 2011 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) today provided notice to holders of its 2.50 percent Convertible Senior Subordinated Notes due 2014 (the "2014 Notes") and 2.00 percent Convertible Senior Subordinated Notes due 2015 (the "2015 Notes") in respect of the Merger (as defined below) of the Company with a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., an Israeli corporation ("Parent"), the consummation of which will constitute a Fundamental Change under each of the Indenture governing the 2014 Notes (the "2014 Indenture") and the Indenture governing the 2015 Notes (the "2015 Indenture"). The 2014 Notes will be convertible in conne...

Cephalon Reported Financial Results for the Second Quarter of 2011

Tuesday August 2nd 2011 04:15:00 PM

Sales For The Period Were $730 Million Basic Income Per Common Share Increased 31 Percent FRAZER, Pa., Aug. 2, 2011 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported second quarter 2011 net sales of $730.1 million, a 2 percent increase compared to net sales of $712.4 million for the second quarter of 2010. Basic income per common share for the period was $1.54 compared to $1.18 for the second quarter of 2010. Excluding amortization expense and certain other items, adjusted net income for the second quarter of 2011 was $142.6 million, a 14 percent decrease versus the same period in 2010. Basic adjusted income per common share for the quarter was $1.86, a 15 percent dec...

Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ

Thursday July 21st 2011 09:32:00 AM

FRAZER, Pa., July 21, 2011 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA® (fentanyl buccal tablet) [C-II] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. Both products are indicated for the management of breakthrough pain in opioid-tolerant patients with cancer. Under this REMS, pharmacies and healthcare professionals who prescribe FENTORA and ACTIQ will enroll by completing an education module and knowledge assessment focused on safety information including appropriate patient selection. Healthcare professionals who prescribe these produ...

Cephalon Shareholders Approve Acquisition by Teva

Thursday July 14th 2011 11:07:00 AM

FRAZER, Pa., July 14, 2011 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that its stockholders voted to approve the Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) proposal to acquire Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction remains under review by the U.S. Federal Trade Commission and the European Commission. Cephalon and Teva continue to operate as two independent companies pending those clearances. About Cephalon Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals aroun...

Cephalon to Release Second Quarter 2011 Earnings Results After the Market Close on August 2, 2011

Wednesday June 29th 2011 10:00:00 AM

FRAZER, Pa., June 29, 2011 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) is scheduled to release its second quarter 2011 results via PRNewswire after the market close (approximately 4:10 p.m.) on Tuesday, August 2, 2011. Cephalon will not be holding a conference call to discuss these results. Cephalon Contacts: Media: Fritz Bittenbender O: 1 610 883 5855 C: 1 610 457 7041 fbittenb@cephalon.com Natalie de Vane O: 1 610 727 6536 C: 1 610 999 8756 ndevane@cephalon.com Investors: Cephalon Contacts Chip Merritt O: 1 610 738 6376 cmerritt@cephalon.com Joseph Marczely O: 1 610 883 5894 jmarczely@cephalon.com SOURCE: Cephalon, Inc.

Cephalon Presents Encouraging Results of Obatoclax in Extensive-Stage Small Cell Lung Cancer at ASCO Annual Meeting

Tuesday June 7th 2011 09:18:00 AM

(FRAZER, Pa.,) June 7, 2011 – Today, Cephalon presented new phase 2 data on an investigational compound, obatoclax, at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill. The data show that patients with extensive-stage small cell lung cancer receiving obatoclax in addition to standard chemotherapy demonstrated a trend toward improved overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) when compared to chemotherapy alone. This is the first presentation of solid tumor data for the Company following its acquisition of Gemin X in March 2011, which developed the drug. Obatoclax expands the Cephalon portfolio in oncology beyond ...

Cephalon Granted Temporary Restraining Order in AMRIX® Patent Litigation

Friday May 20th 2011 02:10:00 PM

FRAZER, Pa., May 20, 2011 /PRNewswire via COMTEX/ -- Today, the United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon, Inc. (NASDAQ: CEPH), and Eurand, Inc., for a Temporary Restraining Order (TRO) enjoining Mylan Pharmaceuticals Inc., and Mylan Inc., from manufacturing, using, offering to sell or selling its cyclobenzaprine hydrochloride extended-release capsules, a generic version of Cephalon's branded product AMRIX®. The TRO remains in effect pending appeal. "We are very pleased with the Court's decision to grant our request for a TRO," said Jerry Pappert, Executive Vice President and General Counsel for Cephalon. "We remain confident ...

Cephalon Recognizes National Night Shift Worker's Day, Honors America's Shift Workers

Wednesday May 11th 2011 09:06:00 AM

New Video Asks the Public to "Shift Assumptions" About Shift Work and Learn about Shift Work Disorder FRAZER, Pa., May 11, 2011 /PRNewswire via COMTEX/ -- Today, Cephalon, Inc. (NASDAQ: CEPH) recognizes those who stay awake to keep our society moving while the rest of us are sleeping by honoring National Night Shift Workers Day and introducing a new video, "Shift Your Assumptions," as a tribute to shift workers. According to the U.S. Department of Labor, over 15 million Americans work odd hours or non-traditional shifts and may be at risk for a medical condition called shift work disorder, in which their body's clock is out of sync with their work schedule. As part of The Wake-Up Squad(SM)...

Cephalon Presents Positive Results with NUVIGIL in Largest Shift Work Disorder Trial Ever Conducted

Friday May 6th 2011 08:32:00 AM

Study Shows Efficacy of NUVIGIL Late in Shift, Including Commute Home FRAZER, Pa., May 6, 2011 /PRNewswire via COMTEX/ -- At the Society of General Internal Medicine's 34th Annual Meeting in Phoenix, Ariz. today, Cephalon, Inc. (Nasdaq: CEPH) presented positive results from a phase IV trial of nearly 400 people with excessive sleepiness associated with shift work disorder. In the trial, NUVIGIL® (armodafinil) Tablets [C-IV] improved shift-workers' overall clinical condition late in their shifts (i.e., 4:00 a.m. to 8:00 a.m.), including the commute home, compared to placebo. The key secondary endpoint of the study was to assess global function, as measured by the Global Assessment of Functi...